Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom FisherZacks Investment Research • 06/03/24
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorBusiness Wire • 05/29/24
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 05/09/24
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsGlobeNewsWire • 03/27/24
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's CancerGlobeNewsWire • 03/18/24
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 02/29/24
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayGlobeNewsWire • 01/18/24
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentGlobeNewsWire • 01/05/24
PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower PriceSeeking Alpha • 11/14/23
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 11/09/23
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/16/23
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationGlobeNewsWire • 10/12/23
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarGlobeNewsWire • 10/11/23
Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?Zacks Investment Research • 10/06/23
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/20/23
Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a BetZacks Investment Research • 08/30/23
PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 08/29/23
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 08/09/23
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/06/23
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 05/10/23
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate HighlightsGlobeNewsWire • 03/01/23
Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?Zacks Investment Research • 12/08/22